Q-omics provides the consensus-scored ERICH5 profile across patient tissues and cancer cell-line models. ERICH5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ERICH5 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ERICH5 RNA expression shows 15,415 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where ERICH5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERICH5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERICH5 survival associations across molecular data types. ERICH5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERICH5 RNA expression–survival associations across cancer types. High ERICH5 expression shows unfavorable associations in ESCA, LUAD and THYM, but favorable associations in KIRC, BRCA and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ERICH5 RNA expression.
This table summarizes ERICH5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ERICH5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERICH5 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, LUAD, KIRP and THCA. The KICH box plot shows higher ERICH5 RNA expression in normal versus tumor tissue (log2 FC = −3.032, t-test p < 0.001).
This table shows molecular features associated with ERICH5 in patient tissues and cancer cell lines. In patient samples, ERICH5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ERICH5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
